These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1963497)

  • 41. Anxiolytics antagonize yohimbine-induced central noradrenergic activity: a concomitant in vivo voltammetry-electrophysiology model of anxiety.
    Crespi F
    J Neurosci Methods; 2009 May; 180(1):97-105. PubMed ID: 19427535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anxiolytic-like effect of 5-HT(2) ligands and benzodiazepines co-administration: comparison of two animal models of anxiety (the four-plate test and the elevated plus maze).
    Massé F; Nic Dhonnchadha BA; Hascoët M; Bourin M
    Behav Brain Res; 2007 Feb; 177(2):214-26. PubMed ID: 17175036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressant-anxiolytic interactions: involvement of the benzodiazepine-GABA and serotonin systems.
    Suranyi-Cadotte BE; Bodnoff SR; Welner SA
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):633-54. PubMed ID: 1705717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional topography of serotonergic systems supports the Deakin/Graeff hypothesis of anxiety and affective disorders.
    Paul ED; Lowry CA
    J Psychopharmacol; 2013 Dec; 27(12):1090-106. PubMed ID: 23704363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of GABA in the pathophysiology and treatment of anxiety disorders.
    Nemeroff CB
    Psychopharmacol Bull; 2003; 37(4):133-46. PubMed ID: 15131523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The possible role of locus coeruleus noradrenergic activity in anxiety-panic.
    Redmond DE
    Clin Neuropharmacol; 1986; 9 Suppl 4():40-2. PubMed ID: 3032432
    [No Abstract]   [Full Text] [Related]  

  • 47. [Anxiety receptors: new pharmacological approach (author's transl)].
    Le Fur G
    Encephale; 1982; 8(2):145-50. PubMed ID: 6125375
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psychobiology of anxiety and anxiety disorders.
    Rainey JM; Nesse RM
    Psychiatr Clin North Am; 1985 Mar; 8(1):133-44. PubMed ID: 2986083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacology of human anxiety.
    Nutt DJ
    Pharmacol Ther; 1990; 47(2):233-66. PubMed ID: 1975444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Central serotonin receptors. Principal fundamental and functional aspects. Therapeutic applications].
    Moulignier A
    Rev Neurol (Paris); 1994; 150(1):3-15. PubMed ID: 7801037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serotonin function in panic disorders. The effect of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment.
    Charney DS; Heninger GR
    Arch Gen Psychiatry; 1986 Nov; 43(11):1059-65. PubMed ID: 3767596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test.
    Massé F; Hascoët M; Dailly E; Bourin M
    Psychopharmacology (Berl); 2006 Jan; 183(4):471-81. PubMed ID: 16307296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in the drug treatment of anxiety disorders.
    Pohl R; Rainey JM; Gershon S
    Psychopathology; 1984; 17 Suppl 1():6-14. PubMed ID: 6369369
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Olanzapine counteracts stress-induced anxiety-like behavior in rats.
    Locchi F; Dall'olio R; Gandolfi O; Rimondini R
    Neurosci Lett; 2008 Jun; 438(2):146-9. PubMed ID: 18455305
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction.
    Dierssen M; Gratacòs M; Sahún I; Martín M; Gallego X; Amador-Arjona A; Martínez de Lagrán M; Murtra P; Martí E; Pujana MA; Ferrer I; Dalfó E; Martínez-Cué C; Flórez J; Torres-Peraza JF; Alberch J; Maldonado R; Fillat C; Estivill X
    Neurobiol Dis; 2006 Nov; 24(2):403-18. PubMed ID: 16963267
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action.
    Shephard RA
    Life Sci; 1987 Jun; 40(25):2429-36. PubMed ID: 2884549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Panic disorder: a presynaptic serotonin defect?
    Kahn RS; van Praag HM
    Psychiatry Res; 1990 Feb; 31(2):209-10. PubMed ID: 2326399
    [No Abstract]   [Full Text] [Related]  

  • 58. The GABAA-BZR complex as target for the development of anxiolytic drugs.
    Trincavelli ML; Da Pozzo E; Daniele S; Martini C
    Curr Top Med Chem; 2012; 12(4):254-69. PubMed ID: 22204488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The serotonin-1A receptor in anxiety disorders.
    Akimova E; Lanzenberger R; Kasper S
    Biol Psychiatry; 2009 Oct; 66(7):627-35. PubMed ID: 19423077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The pharmacologic treatment of anxiety disorders: a review of progress.
    Ravindran LN; Stein MB
    J Clin Psychiatry; 2010 Jul; 71(7):839-54. PubMed ID: 20667290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.